Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease
Lists
Only you see this
Abstract
We have developed a coevolutionary method for the computational design of HIV-1 protease inhibitors selected for their ability to retain efficacy in the face of protease mutation. For HIV-1 protease, typical drug design techniques are shown to be ineffective for the design of resistance-evading inhibitors: An inhibitor that is a direct analogue of one of the natural substrates will be susceptible to resistance mutation, as will inhibitors designed to fill the active site of the wild-type or a mutant enzyme. Two design principles are demonstrated: (i) For enzymes with broad substrate specificity, such as HIV-1 protease, resistance-evading inhibitors are best designed against the immutable properties of the active site-the properties that must be conserved in any mutant protease to retain the ability to bind and cleave all of the native substrates. (ii) Robust resistance-evading inhibitors can be designed by optimizing activity simultaneously against a large set of mutant enzymes, incorporating as much of the mutational space as possible.
BibTeX
@inproceedings{rosin1999coevolutionary,
author = {Christopher D. Rosin and Richard K. Belew and Garrett M. Morris and Arthur J. Olson and David S. Goodsell},
title = {{Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease}},
booktitle = {Proceedings of the National Academy of Sciences},
year = {1999},
doi = {10.1073/pnas.96.4.1369},
}Loading related content...